Hadassah Medical Center has agreed to conduct its ALS clinical trials for BrainStorm Cell Therapeutics Inc., these trials will be held at the Hadassah Ein Kerem Hospital.
Professor Dimitrios Karussis, of Hadassah's Department of Neurology, and the Principal Investigator from Hadassah, stated: “Professor Ben Hur, the Head of the department of Neurology, and I, strongly believe in BrainStorm and its technology. We are delighted to join our efforts at Hadassah with BrainStorm and perform the first clinical trials in ALS, with these types of modified stem cells. Based on our previous clinical experience with mesenchymal stem cells and the impressive preclinical data from BrainStorm, and after receiving final approval of the Ministry of Health, we believe that together we may achieve a breakthrough for the treatment of people suffering from ALS.”
“We are extremely pleased with this agreement with Hadassah,” stated Rami Efrati, CEO of BrainStorm. “Hadassah is a world renowned medical organization with proficiency in stem cell therapy and has been providing stem cell treatments to patients for quite some time. This agreement provides BrainStorm with the medical expertise and support needed to conduct its first ALS clinical trials at a leading medical center in Israel and the Middle East. Along with the funds we secured last week, we now have in place all that we need to proceed with our ALS clinical trials and only await approval from the Israeli Ministry of Health which we hope we will receive in the coming weeks.”
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
